P Neumair
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
Jul 28, 2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Jul 28, 2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
Apr 15, 2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Apr 15, 2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus